ApoA-I inhibitors are compounds that belong to a chemical class designed to interact with and modulate the activity of apolipoprotein A-I (apoA-I). ApoA-I is a protein that plays a crucial role in lipid metabolism and transport, particularly in the formation of high-density lipoproteins (HDL) or good cholesterol. These inhibitors are developed to target the binding sites or interactions of apoA-I with lipids and other proteins involved in lipoprotein assembly and function.
By targeting apoA-I, these inhibitors provide a means to explore the intricate processes of HDL formation and cholesterol transport within the body. ApoA-I inhibitors enable researchers to investigate how modulating apoA-I's interactions with lipids influences the assembly, stability, and functionality of HDL particles. Additionally, studying the effects of apoA-I inhibitors may offer insights into their roles in cardiovascular health, lipid disorders, and other related conditions. Overall, apoA-I inhibitors serve as valuable tools for unraveling the complex interplay of proteins and lipids in maintaining lipid homeostasis and overall metabolic balance.
VER TAMBIÉN ....
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Anacetrapib | 875446-37-0 | sc-364404 sc-364404A | 10 mg 50 mg | ¥6938.00 ¥20138.00 | ||
Inhibidor de CETP que modula los niveles de ApoA-I y el metabolismo lipídico relacionado. | ||||||
Dalcetrapib | 211513-37-0 | sc-364479 sc-364479A | 10 mg 50 mg | ¥8123.00 ¥21436.00 | ||
Inhibidor de CETP que afecta a los niveles de ApoA-I y al metabolismo lipídico. | ||||||
RVX 208 | 1044870-39-4 | sc-472700 | 10 mg | ¥3836.00 | ||
Aumenta la transcripción de ApoA-I mediante la inhibición del bromodominio BET. | ||||||